Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trialHIV 감염, 항레트로바이러스 경험이 없는 성인에서 표준 용량 대비 저용량 테노포비르 디소프록실 푸마르산염 및 에파비렌즈의 효능 및 안전성: 다기관, 무작위, 비열등성 시험Article Published on 2020-05-042022-09-06 Journal: Emerging Microbes & Infections [Category] Communicable Disease, [키워드] 95% CI adverse event adverse events antiretroviral ARV assigned change comparable dose drug efavirenz Efficacy evaluate filtration rate fumarate glomerular filtration rate HIV HIV-1 HIV-1 infection infected patients initial intention-to-treat analysis lamivudine low dose lower dose lower toxicity multicentre non-inferiority non-inferiority margin non-inferiority trial occurred Open-label participant primary endpoint proportion Randomized Randomly receive receiving reduced regimen safety profile Standard dose Support tenofovir tenofovir disoproxil tenofovir disoproxil fumarate therapy Toxicity Treatment treatment difference Trial two groups [DOI] 10.1080/22221751.2020.1752609 PMC 바로가기 [Article Type] Article